Allergan ($AGN), which this month completed the sale of its Actavis generics unit to Teva ($TEVA), is still cleaning up Actavis business, like the recall of tens of thousands of bottles of a diabetes drug.
According to the most recent FDA Enforcement Report, the drugmaker is recalling 5 lots, consisting of 167,152 bottles, of Glipizide, a treatment for Type 2 diabetes. The class II recall began after stability testing determined the drugs exceeded dissolution specification rates for the 10-hour testing point. The product was made for Actavis by contractor Patheon.
Actavis has had some problems with contractors recently. The Dublin-based company earlier this year voluntarily recalled 447,150 bottles, of ciprofloxacin ophthalmic solution that was manufactured by Hi-Tech Pharmacal, a unit of Lake Forest, IL-based Akorn ($AKRX).
Earlier this month, Allergan completed the sale of Actavis to Teva for $40 billion. Israel-based Teva, the largest generics maker in the word, also agreed to buy Actavis U.S. distribution unit, Anda, for another $500 million. With the deal, Teva CEO Erez Vigodman has pledged to increase the drug company’s revenue by as much as 40% by 2019.
- access the recall here
Related Articles:
Akorn's Hi-Tech is the source of large Actavis recall
Allergan’s Actavis recalls nearly 600,000 bottles of ADHD drug
Teva wants Allergan's distribution biz now that $40B drug deal has closed